Chemotherapy Response and Survival of Inflammatory Breast Cancer by Hormone Receptor- and HER2-defined Molecular Subtypes Approximation: an Analysis from the National Cancer Database

Overview

Journal J Cancer Res Clin Oncol

Specialty Oncology

Date 2016 Oct 6

PMID 27704268

Citations 18

Authors

Jieqiong Liu

Kai Chen

Wen Jiang

Kai Mao

Shunrong Li

Min Ji Kim

Qiang Liu

Lisa K Jacobs

Affiliations

Soon will be listed here.

Abstract

Purpose: To study the impact of hormone receptor (HR)- and human epidermal growth factor receptor 2 (HER2)-defined subtypes on survival of inflammatory breast cancer (IBC), and to determine whether sensitivity to neoadjuvant chemotherapy (NAC) varies with subtypes in a large IBC population.

Methods: We analyzed 593 IBCs with known HR/HER2 statuses between 2010 and 2011 from National Cancer Database. We compared pathologic complete response (pCR) rates among four molecular subtypes by Chi-square test. Overall survival (OS) was compared among four subtypes and patients with or without pCR using log-rank test. Multivariate Cox model was performed to identify the impact of molecular subtype and other prognostic factors on OS.

Results: Of the 593 patients included, 231 (39.0 %) patients had HR+/HER2- tumors, 98 (16.5 %) had HR+/HER2+ disease, 112 (18.9 %) were HR-/HER2 + patients, and 152 (25.6 %) had triple-negative subtype. The pCR rates differed significantly by subtype (P < 0.001): HR-/HER2+ showed the highest, and HR+/HER2- exhibited the lowest. Multivariate analysis showed that triple-negative and HR+/HER2- IBCs had significantly worse survival compared with HR+/HER2+ or HR-/HER2+ subtype (P < 0.01 for all comparisons). Additional factors associated with worse OS included more comorbidities, lack or incomplete surgical resection, absence of radiotherapy, lack of hormone therapy, and more advanced stage.

Conclusions: IBC is an aggressive heterogeneous disease with distinct molecular subtypes associated with differential outcomes and sensitivities to NAC. Unlike in noninflammatory breast cancer, in IBC HR + disease was not associated with favorable prognosis. Triple-negative and HR+/HER2- subtypes are independent predictors for suboptimal OS in IBC.

Citing Articles

Trends in Guideline-Concordant Care for Inflammatory Breast Cancer.

Tadros A, Diskin B, Sevilimedu V, Xu A, Vingan P, Nelson J JAMA Netw Open. 2025; 8(2):e2454506.

PMID: 40009385 PMC: 11866030. DOI: 10.1001/jamanetworkopen.2024.54506.

α-Parvin Expression in Breast Cancer Tissues: Correlation with Clinical Parameters and Prognostic Significance.

Takeda M, Ito H, Kitahata K, Sato S, Nishide A, Gamo K Cells. 2024; 13(18.

PMID: 39329755 PMC: 11430769. DOI: 10.3390/cells13181572.

Bicalutamide Enhances Conventional Chemotherapy in In Vitro and In Vivo Assays Using Human and Canine Inflammatory Mammary Cancer Cell Lines.

Crespo B, Illera J, Silvan G, Lopez-Plaza P, Herrera de la Muela M, de la Puente Yague M Int J Mol Sci. 2024; 25(14).

PMID: 39063165 PMC: 11276844. DOI: 10.3390/ijms25147923.

Treatment Response, Tumor Infiltrating Lymphocytes and Clinical Outcomes in Inflammatory Breast Cancer-Treated with Neoadjuvant Systemic Therapy.

De Schepper M, Nguyen H, Richard F, Rosias L, Lerebours F, Vion R Cancer Res Commun. 2023; 4(1):186-199.

PMID: 38147006 PMC: 10807408. DOI: 10.1158/2767-9764.CRC-23-0285.

Low Rates of Local-Regional Recurrence Among Inflammatory Breast Cancer Patients After Contemporary Trimodal Therapy.

Adesoye T, Everidge S, Chen J, Sun S, Teshome M, Valero V Ann Surg Oncol. 2023; 30(10):6232-6240.

PMID: 37479842 DOI: 10.1245/s10434-023-13906-5.

References

Gonzalez-Angulo A, Litton J, Broglio K, Meric-Bernstam F, Rakkhit R, Cardoso F . High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. J Clin Oncol. 2009; 27(34):5700-6. PMC: 2792998. DOI: 10.1200/JCO.2009.23.2025. View

Lehmann B, Bauer J, Chen X, Sanders M, Chakravarthy A, Shyr Y . Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011; 121(7):2750-67. PMC: 3127435. DOI: 10.1172/JCI45014. View

Rueth N, Lin H, Bedrosian I, Shaitelman S, Ueno N, Shen Y . Underuse of trimodality treatment affects survival for patients with inflammatory breast cancer: an analysis of treatment and survival trends from the National Cancer Database. J Clin Oncol. 2014; 32(19):2018-24. PMC: 4067942. DOI: 10.1200/JCO.2014.55.1978. View

Parker J, Mullins M, Cheang M, Leung S, Voduc D, Vickery T . Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol. 2009; 27(8):1160-7. PMC: 2667820. DOI: 10.1200/JCO.2008.18.1370. View

Dawood S, Ueno N, Valero V, Woodward W, Buchholz T, Hortobagyi G . Differences in survival among women with stage III inflammatory and noninflammatory locally advanced breast cancer appear early: a large population-based study. Cancer. 2011; 117(9):1819-26. DOI: 10.1002/cncr.25682. View

Kyndi M, Sorensen F, Knudsen H, Overgaard M, Nielsen H, Overgaard J . Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group. J Clin Oncol. 2008; 26(9):1419-26. DOI: 10.1200/JCO.2007.14.5565. View

Li J, Gonzalez-Angulo A, Allen P, Yu T, Woodward W, Ueno N . Triple-negative subtype predicts poor overall survival and high locoregional relapse in inflammatory breast cancer. Oncologist. 2011; 16(12):1675-83. PMC: 3248766. DOI: 10.1634/theoncologist.2011-0196. View

Schlichting J, Soliman A, Schairer C, Schottenfeld D, Merajver S . Inflammatory and non-inflammatory breast cancer survival by socioeconomic position in the Surveillance, Epidemiology, and End Results database, 1990-2008. Breast Cancer Res Treat. 2012; 134(3):1257-68. PMC: 4291081. DOI: 10.1007/s10549-012-2133-2. View

Jezequel P, Loussouarn D, Guerin-Charbonnel C, Campion L, Vanier A, Gouraud W . Gene-expression molecular subtyping of triple-negative breast cancer tumours: importance of immune response. Breast Cancer Res. 2015; 17:43. PMC: 4389408. DOI: 10.1186/s13058-015-0550-y. View

10.

Prat A, Perou C . Deconstructing the molecular portraits of breast cancer. Mol Oncol. 2010; 5(1):5-23. PMC: 5528267. DOI: 10.1016/j.molonc.2010.11.003. View

11.

Logan B, Wang H, Zhang M . Pairwise multiple comparison adjustment in survival analysis. Stat Med. 2005; 24(16):2509-23. DOI: 10.1002/sim.2125. View

12.

Levine P, Steinhorn S, Ries L, Aron J . Inflammatory breast cancer: the experience of the surveillance, epidemiology, and end results (SEER) program. J Natl Cancer Inst. 1985; 74(2):291-7. View

13.

Hance K, Anderson W, Devesa S, Young H, Levine P . Trends in inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program at the National Cancer Institute. J Natl Cancer Inst. 2005; 97(13):966-75. PMC: 2844937. DOI: 10.1093/jnci/dji172. View

14.

Masuda H, Brewer T, Liu D, Iwamoto T, Shen Y, Hsu L . Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor- and HER2-defined subtypes. Ann Oncol. 2013; 25(2):384-91. PMC: 3905780. DOI: 10.1093/annonc/mdt525. View

15.

Matro J, Li T, Cristofanilli M, Hughes M, Ottesen R, Weeks J . Inflammatory breast cancer management in the national comprehensive cancer network: the disease, recurrence pattern, and outcome. Clin Breast Cancer. 2014; 15(1):1-7. PMC: 4422394. DOI: 10.1016/j.clbc.2014.05.005. View

16.

Chen X, Li J, Gray W, Lehmann B, Bauer J, Shyr Y . TNBCtype: A Subtyping Tool for Triple-Negative Breast Cancer. Cancer Inform. 2012; 11:147-56. PMC: 3412597. DOI: 10.4137/CIN.S9983. View

17.

Zhou J, Yan Y, Guo L, Ou H, Hai J, Zhang C . Distinct outcomes in patients with different molecular subtypes of inflammatory breast cancer. Saudi Med J. 2014; 35(11):1324-30. PMC: 4362150. View

18.

Nguyen P, Taghian A, Katz M, Niemierko A, Abi Raad R, Boon W . Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. J Clin Oncol. 2008; 26(14):2373-8. DOI: 10.1200/JCO.2007.14.4287. View

19.

Hammond M, Hayes D, Dowsett M, Allred D, Hagerty K, Badve S . American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med. 2010; 134(7):e48-72. DOI: 10.5858/134.7.e48. View

20.

Carey L, Perou C, Livasy C, Dressler L, Cowan D, Conway K . Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006; 295(21):2492-502. DOI: 10.1001/jama.295.21.2492. View